KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024
May 24 2024 - 6:30AM
Business Wire
– Late-breaking presentations for sebetralstat
phase 3 KONFIDENT and KONFIDENT-S trials on Friday, May 31 –
– Multiple real-world data presentations show
that delay of injectable on-demand treatment for HAE attacks
remains common -
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced
the acceptance of multiple abstracts and a symposium at the
European Academy of Allergy and Clinical Immunology (EAACI)
Congress 2024 taking place in Valencia, Spain from May 31-June
3.
Presentations will include:
Friday, May 31
- Oral Sebetralstat for On-demand Treatment of Hereditary
Angioedema: Phase 3 KONFIDENT Trial Results: Marc Riedl,
Henriette Farkas, Emel Ayg�ren-Pürsün, Fotis Psarros, Daniel
Soteres, Maria Staevska, Mauro Cancian, David Hagin, Daisuke Honda,
Isaac Melamed, Sinisa Savic, Marcin Stobiecki, Paula Busse, Eunice
Dias de Castro, Nancy Agmon-Levin, Richard Gower, Aharon Kessel,
Marcin Kurowski, Ramon Lleonart, Vesna Grivcheva Panovska, H. James
Wedner, Paul Audhya, James Hao, Matthew Iverson, Michael Smith,
Christopher Yea, William Lumry, Andrea Zanichelli, Jonathan
Bernstein, Marcus Maurer, Danny Cohn.
Results shared as a Late Oral Abstract Session on Clinical Trials
on Friday, May 31, 2024, from 4:45-6:15 p.m. CEST in the Artificial
intelligence and Data science Hub.
- Sebetralstat as Oral On-demand Treatment for Hereditary
Angioedema: Interim Analysis of Demographics and Attack
Characteristics from the Open-label KONFIDENT-S Trial:
Henriette Farkas, Marc Riedl, Emel
Ayg�ren-Pürsün, William Lumry, Andrea Zanichelli, James Hao,
Matthew Iverson, Michael Smith, Christopher Yea, Paul Audhya,
Jonathan Bernstein, Marcus Maurer, Danny Cohn. Results shared as a
Late poster/ePoster presentation and Q&A on Friday, May 31,
2024, from 12:00-1:00 p.m. CEST on Level 3 of the Central Forum in
the Poster Zone
Saturday, June 1
- KalVista Symposium - Closing Gaps in HAE Management:
Addressing Delays in On-Demand Treatment: Presenters - Doug
Jones, MD, Thomas Bettgereit, MD, Emily Carne, MSc, Danny Cohn, MD,
PhD. Symposium takes place on Saturday, June 1, 2024 from 6:45-7:45
p.m. CEST in the Alicante Room. All conference attendees and hybrid
virtual delegates are welcome to attend
- A Sensitive and Specific Assay to Characterize Plasma
Kallikrein Activity in Plasma from Hereditary Angioedema (HAE)
Patients: Daniel Lee, A. Ghannam,
Nivetha Murugesan, D. Vincent, A. Mogg, M. Smith, Sally Hampton,
Edward Feener. Results shared as an Oral Abstract Session (OAS) on
Saturday, June 1, 2024, from 4:45-6:15 p.m. CEST in the Bilbao
Room
- Delayed On-demand Treatment of Hereditary Angioedema
Attacks: Patient Perceptions and Associated Barriers: Sinisa
Savic, Tariq El-Shanawany, Padmalal Gurugama, Rashmi Jain, Sherry Danese, Julie Ulloa, Vibha
Desai, Paul Audhya, Patrick Yong. Results shared as a poster/
ePoster presentation and Q&A on Saturday, June 1, 2024, from
12:00-1:00 p.m. CEST on Level 3 of the Central Forum in the Poster
Zone
- Anxiety Associated with On-Demand Treatment for Hereditary
Angioedema Attacks: Patrick Yong,
Tariq El-Shanawany, Padmalal Gurugama, Rashmi Jain, Sherry Danese,
Julie Ulloa, Vibha Desai, Paul Audhya, Sinisa Savic. Results shared
as a poster/ePoster presentation and Q&A on Saturday, June 1,
2024, from 12:00-1:00 p.m. CEST on Level 3 of the Central Forum in
the Poster Zone
- Unmet Needs Associated with Non-androgen Injectable
Long-term Prophylaxis Therapies for HAE: William Lumry, Alan Baptist, Daniel Soteres,
Michael Manning, Kieran Wynne-Cattanach, Lauretta Birija, Paul K.
Audhya, Alice Wang, Tomas Andriotti, Vibha Desai. Results shared as
a poster/ePoster presentation and Q&A on Saturday, June 1,
2024, from 12:00-1:00 p.m. CEST on Level 3 of the Central Forum in
the Poster Zone
Sunday, June 2
- Hereditary Angioedema (HAE) Patients Answer: Why Do Attacks
Go Untreated?: Cristine Radojicic,
Paula Busse, Maeve O’Connor, Sherry Danese, Julie Ulloa, Vibha
Desai, Tomas Andriotti, Paul K. Audhya, Sandra Christiansen.
Results shared as a Flash Talks Session on Sunday, June 2, 2024,
from 3:00-4:30 p.m. CEST in the Palma Room
- Attack Characteristics in Patients with Hereditary
Angioedema Receiving Non-Androgen Long-term Prophylaxis:
William Lumry, Alan Baptist, Daniel
Soteres, Michael Manning, Lucy Earl, Hannah Connolly, Paul K.
Audhya, Alice Wang, Tomas Andriotti, Vibha Desai. Results shared as
a Flash Talks Session on Sunday, June 2, 2024, from 1:15-2:45 p.m.
CEST in the Palma Room
- Patient-Reported Benefits of Early On-demand Treatment of
HAE Attacks: Hilary Longhurst, Mar
Guilarte, Sally van Kooten, Neil Malloy, Markus Heckmann, Paula
Busse. Results shared as a poster/ePoster presentation and Q&A
on Sunday, June 2, 2024, from 12:00-1:00 p.m. CEST on Level 3 of
the Central Forum in the Poster Zone
- Treatment of HAE Attacks with Anticipated Future Oral
On-demand Therapies as Reported by Patients: Anna Valerieva, Douglas Jones, Sally van Kooten,
Neil Malloy, Markus Heckmann, Stephen Betschel. Results shared as a
poster/ePoster presentation and Q&A on Sunday, June 2, 2024,
from 12:00-1:00 p.m. CEST on Level 3 of the Central Forum in the
Poster Zone
Links to all posters and presentations can be found on the
KalVista website under “Publications”.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a global pharmaceutical
company focused on the development and delivery of oral medicines
for diseases with significant unmet need. KalVista disclosed
positive phase 3 data for the KONFIDENT trial for its oral,
on-demand therapy sebetralstat in February 2024. The Company
anticipates submitting a new drug application to the U.S. Food and
Drug Administration (FDA) for sebetralstat in June 2024 and expects
to file for approval in the UK, Europe, and Japan later in
2024.
For more information about KalVista, please visit
www.kalvista.com.
Forward-Looking Statements
This press release contains "forward-looking" statements within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: "anticipate,"
"intend," "plan," "goal," "seek," "believe," "project," "estimate,"
"expect," "strategy," "future," "likely," "may," "should," "will"
and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, timing or
outcomes of communications with the FDA or other international
regulatory agencies, our expectations about safety and efficacy of
our product candidates, our ability to obtain regulatory approvals
for sebetralstat and other candidates in development within our
expected timelines or at all, our success in engaging with
potential commercial partners, the success of any efforts to
commercialize sebetralstat, the ability of sebetralstat and other
candidates in development to treat HAE or other diseases, our
ability to commence pediatric trials of sebetralstat and develop an
ODT formulation, the future progress and potential success of our
oral Factor XIIa program, our ability to reduce spending on
discovery and preclinical activities, and our expectation to become
cash flow positive. Further information on potential risk factors
that could affect our business and financial results are detailed
in our filings with the Securities and Exchange Commission,
including in our annual report on Form 10-K for the year ended
April 30, 2023, our quarterly reports on Form 10-Q, and our other
reports that we may make from time to time with the Securities and
Exchange Commission. We undertake no obligation to publicly update
any forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240524679559/en/
KalVista Pharmaceuticals, Inc. Jarrod Aldom Vice
President, Corporate Communications (201) 705-0254
jarrod.aldom@kalvista.com
Ryan Baker Head, Investor Relations (617) 771-5001
ryan.baker@kalvista.com
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From May 2024 to Jun 2024
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Jun 2023 to Jun 2024